Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 567 participants.

Also called NCT05366868

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 567 participants (planned count) (from the registry)
Sponsor
National Center for Global Health and Medicine, Japan (from the registry)
Registry
  • NCT NCT05366868
  • jRCT jRCTs051180211
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05366868. Randomized; no masking; primary purpose treatment. Start 2022-05-26 (actual); primary completion 2026-08-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Imeglimin
Intervention (Drug)
Metformin
Intervention (Drug)
Vildagliptin
Lead sponsor
National Center for Global Health and Medicine, Japan (class: other government)
Collaborator
Sumitomo Pharma Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05366868
Content hash
13be24372283d446ba8b0a2d6633bbc7ad02a75846e79259c0d05bba2acb56b6